To date, the tumor-promoting roles of STAT3 signaling in NSCLC that have been well characterized include promoting angiogenesis, cell survival, cancer cell stemness, drug resistance, and evasion of anti-tumor immunity (Figure 3). This evidence concerns the gene STAT3 and non-small cell lung carcinoma.